N(6)-[H2N-NLFQVVHNSYNRPAYSPG-N-{54-amino-7,10,18,21,29,32,40,43,51,54-decaoxo-3,14,25,36,47-pentakis-[5-({2-[alpha-L-Rhap-(1->3)-beta-D-GlcpO]ethyl}sulfinyl)pentanoyl]-3,6,11,14,17,22,25,28,33,36,39,44,47,50-tetradecaazatetrapentacont-1-yl}]adipamido group
n(6)-[h2n-nlfqvvhnsynrpayspg-n-{54-amino-7,10,18,21,29,32,40,43,51,54-decaoxo-3,14,25,36,47-pentakis-[5-({2-[alpha-l-rhap-(1->3)-beta-d-glcpo]ethyl}sulfinyl)pentanoyl]-3,6,11,14,17,22,25,28,33,36,39,44,47,50-tetradecaazatetrapentacont-1-yl}]adipamido group
An organic group consisting of an H<small><sub>2</sub></small>N-NLFQVVHNSYNRPAYSPG-<em>N</em>-{54-amino-7,10,18,21,29,32,40,43,51,54-decaoxo-3,14,25,36,47-pentakis-[5-({2-[α-<small>L</small>-Rha<em>p</em>-(1→3)-β-<small>D</small>-Glc<em>p</em>O]ethyl}sulfinyl)pentanoyl]-3,6,11,14,17,22,25,28,33,36,39,44,47,50-tetradecaazatetrapentacont-1-yl} group linked to the terminal N of an adipamido group. PMID:27091615 reports several of these being linked to the CRM<small><sub>197</sub></small> immunogenic carrier protein to form a semisynthetic glycoconjugate.